Powder: -20°C for 3 years | In solvent: -80°C for 1 year
M435-1279 is a UBE2T inhibitor. M435-1279 blocks UBE2T-mediated degradation of RACK1, leading to inhibit the hyperactivation of Wnt/β-catenin signaling pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 193.00 | |
25 mg | In stock | $ 372.00 | |
50 mg | In stock | $ 556.00 | |
100 mg | In stock | $ 783.00 | |
500 mg | In stock | $ 1,650.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 145.00 |
Description | M435-1279 is a UBE2T inhibitor. M435-1279 blocks UBE2T-mediated degradation of RACK1, leading to inhibit the hyperactivation of Wnt/β-catenin signaling pathway. |
In vitro | M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of AGS, HGC27, and MKN45 cells. M435-1279 (0, 4, 8, 12, 16, 20 μM) inhibits the cell viability with IC50s of 16.8, 11.88, 7.76, 6.93 μM of GES-1, HGC27, AGS MKN45, cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T protein with a KD value of 50.5 μM. M435-1279 (11.88 μM; 48 h) blocks the ubiquitination of RACK1, leading to inhibit the hyperactivation of the Wnt/β-catenin pathway[1]. |
In vivo | M435-1279 (5 mg/kg/day; intratumor injection; 18 days) slows the tumor growth. M435-1279 induces higher expression of RACK1 proteins, and lower expression of Ki-67 and β-catenin proteins in intratumor tumors[1]. |
Molecular Weight | 419.47 |
Formula | C18H17N3O5S2 |
CAS No. | 1359431-16-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45.0 mg/mL (107.3 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
M435-1279 1359431-16-5 Ubiquitination E1/E2/E3 Enzyme M435 1279 M4351279 inhibitor inhibit